ArticleCureus2026
Squamous Eccrine Ductal Carcinoma Treated With Adjuvant Radiation Therapy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Squamous eccrine ductal carcinoma (SEDC) is a rare skin cancer with limited academia or documented definitive and/or adjuvant therapeutic options. Retrospective studies report aggressive course, high risk of local recurrence, and/or distant metastasis. Histopathology describes it to possess both squamous and ductal differentiation, causing diagnostic obscurity and misdiagnosis, begetting underdiagnosis, mottling the prognostic course. If perineural or lymphovascular invasion (LVI) is noted, increased risk of local recurrence is evident. With recurrence risk rates in mind, a physician could infer that wide local excision (WLE) with negative margins or Mohs microscopic surgery (MMS) may not be enough for a cure. After WLE, the role of adjuvant radiotherapy is unclear. In our patient, adjuvant radiotherapy was offered to maximize local control.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.